News - Santhera Pharmaceuticals


Current filters:

Santhera Pharmaceuticals

Popular Filters

EMA validates Santhera’s Marketing Authorization Application for Raxone

EMA validates Santhera’s Marketing Authorization Application for Raxone


The European Medicines Agency has validated a Marketing Authorization Application (MAA) for Leber’s…

EuropeOphthalmicsPharmaceuticalRaxoneRegulationSanthera Pharmaceuticals

Santhera muscular dystrophy drug shows success first time in late clinical trial


For the first time, a drug for Duchenne muscular dystrophy (DMD) – from Swiss drugmaker Santhera Pharmaceuticals…

CatenaPharmaceuticalRare diseasesRaxoneResearchSanthera Pharmaceuticals

Positive Ph III results with Santhera’s Catena/Raxone in Duchenne muscular dystrophy


Swiss drugmaker Santhera Pharmaceuticals has released positive Phase III, double-blind, placebo-controlled…

CatenaPharmaceuticalRare diseasesRaxoneResearchSanthera Pharmaceuticals

Santhera re-files for EU approval of Raxone in the treatment of LHON


Swiss drugmaker Santhera Pharmaceuticals has re-filed its Marketing Authorization Application for Raxone…

EuropeOphthalmicsPharmaceuticalRare diseasesRaxoneSanthera Pharmaceuticals

Santhera presents new efficacy data with Raxone for Leber's hereditary optic neuropathy


Swiss specialty drugmaker Santhera Pharmaceuticals says that current data from the expanded access program…

OphthalmicsPharmaceuticalRaxoneResearchSanthera Pharmaceuticals

Santhera's Raxone granted temporary use in France


Switzerland-based Santhera Pharmaceuticals (SIX: SANN) announced today that the French National Agency…

FranceNeurologicalPharmaceuticalRaxoneRegulationSanthera Pharmaceuticals

Santhera regains Catena European rights


Switzerland-based Santhera Pharmaceuticals (SIX: SANN) says that it has reached an agreement with Takeda…

CatenaEuropeLicensingPharmaceuticalRare diseasesSanthera PharmaceuticalsTakeda Pharmaceuticals

Santhera gets exclusive rights from NIH for novel approach to pp multiple sclerosis treatment


Swiss Santhera Pharmaceuticals (SIX: SANN) says that it has obtained an exclusive license from the USA's…

CatenaLicensingNeurologicalPatentsPharmaceuticalSanthera Pharmaceuticals

IDSMB backs continuation of Santhera's Ph III Catena trial in DMD, but now needs partner


Swiss drugmaker Santhera Pharmaceuticals (SIX: SANN) says that the Phase III DELOS study of orally administered…

CatenaLicensingPharmaceuticalRare diseasesResearchSanthera Pharmaceuticals

Good EMA news for Pfizer's Bosulif but not for Santhera's Raxone


Following its monthly meetings last week, the European Medicines Agency the Committee for Medicinal Products…

BiotechnologyBosulifEuropeOncologyOphthalmicsPfizerPharmaceuticalRaxoneRegulationSanthera Pharmaceuticals

Ipsen returns rights to Parkinson’s drug to Santhera


Switzerland’s Santhera Pharmaceuticals (SIX:SANN) and French drugmaker Ipsen (Euronext: IPN) have…

fipamezoleIpsenLicensingNeurologicalPharmaceuticalSanthera Pharmaceuticals

Back to top